The SARS-CoV-2 virus infection quickly crossed the geographical barriers of the place where it emerged in Asia. From an epidemic caused by a respiratory virus in humans, fast, it became a pandemic. This shows us clearly that, despite the knowledge accumulated over the last century, we are still highly vulnerable to the attack of microorganisms, mainly viruses. This is aggravated when the virus in question spreads among humans through the respiratory system, as is the case of SARS-CoV-2, the causative agent of COVID-19. Chemotherapy drugs used in other viral infections were tested for COVID-19 with no positive effects and leaving sequelae in users. Researchers from different areas of the biomedical sciences, including virology, immunology, molecular biology, epidemiology, and many other disciplines, started to spend their time researching the SARS-CoV-2 virus in an emergency way whose primary focus of these researches the development of a vaccine. However, we know that a vaccine against an infectious agent takes years to be developed, tested in all its aspects, and finally released to the general population without posing risks. Therefore, we were faced with significant challenges as soon as the year 2020 began. This Special Issue is dedicated to reviewing the immune response against coronaviruses and SARS-CoV-2 in particular. There are seven contributions from authors from different countries, briefly outlined below.

中文翻译：

---

COVID-19特刊序言

SARS-CoV-2病毒感染迅速越过了它在亚洲出现的地方的地理障碍。从人类呼吸道病毒引起的流行开始，很快就变成了大流行。这清楚地表明，尽管有上个世纪积累的知识，但我们仍然极易受到微生物（主要是病毒）的攻击。当相关病毒通过呼吸系统在人体内传播时，如SARS-CoV-2（COVID-19的病原体）一样，这种情况会加剧。对其他病毒感染中使用的化学治疗药物进行了COVID-19测试，结果没有阳性影响，使用者没有后遗症。来自生物医学科学各个领域的研究人员，包括病毒学，免疫学，分子生物学，流行病学和许多其他学科，开始花时间以紧急方式研究SARS-CoV-2病毒，这些研究的主要重点是疫苗的开发。但是，我们知道，针对传染病的疫苗需要花费数年的时间进行开发，全面测试，并最终释放给普通人群而不会带来任何风险。因此，我们从2020年开始就面临着重大挑战。本期专刊旨在综述针对冠状病毒尤其是SARS-CoV-2的免疫反应。来自不同国家的作者提供了七篇论文，简要概述如下。最终在不构成风险的情况下释放给普通民众。因此，我们从2020年开始就面临着重大挑战。本期专刊旨在综述针对冠状病毒尤其是SARS-CoV-2的免疫反应。来自不同国家的作者提供了七篇论文，简要概述如下。最终在不构成风险的情况下释放给普通民众。因此，我们从2020年开始就面临着重大挑战。本期专刊旨在综述针对冠状病毒尤其是SARS-CoV-2的免疫反应。来自不同国家的作者提供了七篇论文，简要概述如下。